ArticleBMC cancer2018
The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Early kinetics of CA19-9 and CEA after 5-FU-based chemotherapy for gastrointestinal cancers.Discover oncology · 2026Article
- Investigation of a methylated BCAT1 and IKZF1 circulating tumour DNA blood test for monitoring treatment response in patients with colorectal cancer.Journal of cancer research and clinical oncology · 2026Article
- Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer.World journal of gastroenterology · 2026Article
- Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- A study of factors influencing access to MDT among patients with stage III to stage IV colorectal cancer: a national multicenter survey.Frontiers in oncology · 2026Article
- Systemic chemotherapy in patients with unresectable pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasms: a case series.Journal of gastrointestinal oncology · 2025Article
- The prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and prognostic nutritional index for survival in patients with colorectal cancer.Open medicine (Warsaw, Poland) · 2025Article
- CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.Scientific reports · 2023Article
- Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer.International journal of molecular sciences · 2023Article
- Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer.Frontiers in oncology · 2023Article
- Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy.World journal of clinical cases · 2022Article
- Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy.Scientific reports · 2021Article
- Dynamic monitoring of serum specific tumor markers predicts the response to PD-1 blockade and prognosis of patients with malignant tumors.Translational cancer research · 2021Article
- Behavioural Response Alteration inBiomarkers in cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe role of carcinoembryonic antigen (CEA) change patterns in tumor response and long-term outcome is unclear. This study aimed to investigate the correlation between changes in CEA levels and tumor response as a potential prognostic model.
methodsCEA levels were determined from baseline to progression. A χ
resultsAll 114 patients were divided into five groups according to CEA change pattern (A: patients had an initial fast CEA decrease that then turned into a slow increase; B: patients had an initial slow CEA decrease that then turned to a slow increase; C: patients had a continually slow CEA increase; D: patients had a continually fast CEA increase; E: patients had an initial fast CEA decrease that then turned into a fast increase). Patients in Group A had the longest OS and PFS while Group E patients had the shortest OS. Baseline to week 12 and week 12 to week 18 change rates were consistent with tumor response and progression, respectively. An increase in CEA level by ≥2.7% from week 12 to 18 was an independent negative prognostic factor of OS.
conclusionsCEA changes mirror the tumor response to first-line chemotherapy and are associated with prognosis. CEA monitoring may be a substitute for computed tomography during the CEA stable period of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.